ClinicalTrials.gg
RecruitingNCT06209645PERSOSTIMUpdated May 8, 2026

Non-invasive Personalized Transcranial Cortical Neurostimulation for Pain Relief

An interventional study of tDCS (Transcranial Direct Current Stimulation) and tACS (Transcranial Alternating Current Stimulation) in Drug-resistant Neuropathic Pain, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 132 studies in Neuralgia with a site in France — 39 open to participants now, 40 under way, 4 of them phase 3. Neuralgia · France.

Planned enrollment
57th of 102
50 · median 62
Started
2025
with 8 others
No phase
46 of 132
23 open now
Primary completion
2029-01
later than 36 of 39 live
Registered
104th of 132
by date
Lead sponsor
6 of 132
Hospices Civils de Lyon

Among the 132 studies in Neuralgia with a site in France, this one is the 57th largest by planned enrollment of the 102 interventional ones that give a count, is one of 9 that started in 2025, is one of 46 with no phase, reaches primary completion later than 36 of the 39 other live ones, and was the 104th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

39 of the 132 studies in Neuralgia with a site in France are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Neuralgia with a site in France, or all of them as a file.
02

Study summary

Neuropathic pain is a public health problem with less than 50% of patients being relieved by drug treatments.

Surgically implanted motor cortex stimulation represents an invasive therapeutic solution capable of relieving a significant proportion of drug-resistant patients (1 in 2); it cannot, however, be offered to all patients, and is not morbidity-free.

Non-invasive motor cortex stimulation techniques have been refined over the last decade, in particular transcranial repetitive magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), which provide pain relief among almost half of drug-resistant patients with few or no side effects.

To be efficient, cortical stimulation requires the activation of multiple distant networks involved in the cognitive and motivational response to pain; stimulation frequency is a crucial parameter for activating these mechanisms. The match between cortical stimulation frequency and the intrinsic neuronal frequency of the stimulated cortex has recently been suggested as a key determinant of clinical effect. Indeed, the transmission efficiency of an oscillatory network increases when its intrinsic frequency matches that of the stimulus applied to it. Given that human sensorimotor networks spontaneously oscillate at frequencies around 10 and 20 Hertz (Hz), this match could underlie the superior efficacy of transcranial stimulation at these frequencies.

The hypothesis of the study is that the analgesic effect of cortical stimulation will be enhanced if the stimulation frequency resonates with the spontaneous oscillations of the underlying cortex, thus facilitating its connectivity with the remote structures involved in pain control. The investigators propose to test this hypothesis in a population of patients with drug-resistant neuropathic pain, referred to the Pain Evaluation and Treatment Center (CETD) of the Neurological hospital, at the Hospices Civils de Lyon. The overall aim of the project is to compare the efficacy of stimulation at each individual's own rate of oscillation of the motor cortex, against a "classic" stimulation protocol, and against placebo stimulation.

03

Conditions studied

  • Drug-resistant Neuropathic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 80 years
  • Neuropathic pain of more than one year's duration1
  • Failed treatment with tricyclic or tetracyclic antidepressants, antiepileptics and a combination of morphine and a serotonin (5HT) norepinephrine (NA2) reuptake inhibitor, in the absence of .
  • Average pain intensity of at least 4/10 in the month preceding the inclusion visit.
  • Recipient or beneficiary of a social security scheme-

Exclusion criteria

Exclusion Criteria:

  • Chronic non-neuropathic pain or pain associated with progressive pathology, active epilepsy, unhealed scalp wound, impaired comprehension or communication that prevents subjective daily and weekly assessments.
  • Active epilepsy, treated or not
  • Unhealed scalp wound adjacent to EEG recording electrodes or transcranial stimulation application ( to Medical Device (DM) use)
  • Pregnant or breast-feeding women
  • Inability to understand or follow the ins and outs of the study, in particular the need to assess pain intensity on a daily basis or to trace it, possibly with the help of a third party (comprehension or communication disorders).
  • People under guardianship, curatorship or legal protection
  • Persons deprived of their liberty, persons under psychiatric care and persons admitted to a health or social establishment for purposes other than clinical investigation
  • Participation in other research interfering with the present study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    tDCS then tACS

    This group is made up of adult patients with drug-resistant neuropathic pain, who started with tDCS stimulation, followed by tACS stimulation, in accordance with randomization. Each series of each modality comprises 6 sessions spaced 2 weeks apart, the first session being in placebo mode and the following 5 in active mode. Each session lasts 20 minutes. In placebo mode, a 2 miliampere (mA) current is delivered for 30 seconds at the start and at the end of the session, to prevent the patient noticing the difference between placebo and active stimulation. In active mode, the 2mA current is delivered for the duration of the session.

    Device: tDCS (Transcranial Direct Current Stimulation) · Device: tACS (Transcranial Alternating Current Stimulation)

  • Experimental
    tACS then tDCS

    This group is made up of adult patients with drug-resistant neuropathic pain, who started with tACS stimulation, followed by tDCS stimulation, in accordance with randomization. Each series of each modality comprises 6 sessions spaced 2 weeks apart, the first session being in placebo mode and the following 5 in active mode. Each session lasts 20 minutes. In placebo mode, a 2mA current is delivered for 30 seconds at the start and at the end of the session, to prevent the patient noticing the difference between placebo and active stimulation. In active mode, the 2mA current is delivered for the duration of the session.

    Device: tDCS (Transcranial Direct Current Stimulation) · Device: tACS (Transcranial Alternating Current Stimulation)

Interventions

  • DevicetDCS (Transcranial Direct Current Stimulation)

    The tDCS group will be treated with non-invasive motor cortex stimulation. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region. If pain is bilateral, the most painful region will be chosen to be treated.

  • DevicetACS (Transcranial Alternating Current Stimulation)

    The tACS group will be treated with non-invasive motor cortex stimulation. The stimulation series comprises six sessions spaced 2 weeks apart, the first session being placebo. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Stimulation frequency will be set according to the dominant frequency recorded over the motor area. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region.

06

What researchers measure

Primary outcomes

  1. Pain intensity measure

    Comparison of weekly standardized averages of the Numerical rating scale (NRS) values at the end of tACS versus tDCS versus placebo stimulation sessions. Pain scale measurement: pain scale : 1 the minimum and 10 maximum value, 10 the higher score mean a worse outcome.

    Time frame: daily from the beginning until the end of the protocol (15 months)

Secondary outcomes

  1. Percentage of responding patients Percentage of patients responding favorably to stimulation (Z-score <-2) after tACS and conventional tDCS.

    The response is considered favorable if on the NRS scale, compared with the baseline of each participant, there is a pain improvement of: * more than 30% or * more than 2 points or * more than 2 Standard Deviation Pain scale measurement: pain scale : 1 the minimum and 10 maximum value, 10 the higher score means a worse outcome.

    Time frame: daily from the beginning until the end of the protocol (15 months)

  2. Patient's Global Impression of Change (PGIC) Comparison of weekly standardized values of the PGIC at the end of tACS versus tDCS versus placebo stimulation sessions.

    The PGIC is a seven-points scale that allows the patient to rate their overall impression of change 1 minimum value and 7 maximum value, and 7 higher score means worse result.

    Time frame: one a week from the beginning until the end of the protocol (15 months)

  3. Fatigue score Comparison of weekly standardized averages of the fatigue score values at the end of tACS versus tDCS versus placebo stimulation sessions.

    The fatigue score is a ten-points (from 0 to 10) scale that allows the patient to rate their fatigue fatigue scale : 1 the minimum and 10 maximum value, 10 the higher score means a worse outcome.

    Time frame: daily from the beginning until the end of the protocol (15 months)

  4. Sleep score Comparison of weekly standardized averages of the sleep score values at the end of tACS versus tDCS versus placebo stimulation sessions.

    The sleep score is a ten-points (from 0 to 10) scale that allows the patient to rate their quality of sleep with 0= bad quality and 10 = excellent quality Sleep scale : 1 the minimum and 10 maximum value, 10 the higher score means a worse outcome.

    Time frame: daily from the beginning until the end of the protocol (15 months)

  5. Sympathetic Skin Response (SSR) measurement Variation, in patients with hyperalgesia/allodynia, of Sympathetic Skin Response after treatment with tACS versus tDCS versus placebo.

    SSR is an objective measure of patient's arousal. For patients suffering from allodynia, SSR will be measured after touch (brush) and/or heat (laser) stimulation on sensitized region and a symmetrical non-sensitised region SSR is expressed in mV(millivolt). It is a record of a physiological measurement. The minimum value corresponds to the absence of a response greater than the background recorded by the electrodes. There is no maximum value. The change in response is significant if there is a change greater than 30% from baseline.

    Time frame: SSR will be measured in allodynic patients before each stimulation and evaluation session, starting with the first stimulation session until the end of the protocol (15 months)

07

Study locations

1 of 1 sites recruiting
  • Centre d'Evaluation et de Traitement de la Douleur, Hôpital Neurologique Pierre Wertheimer
    Bron, 69677, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jan 2029, 45 months after the start.

Of 249 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 45 months is above that.

Counting every sponsor, half of 267 studies reached it within 24 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2023
First posted
Jan 17, 2024
StartActual
Apr 10, 2025
Primary completionEst.
Jan 10, 2029
CompletionEst.
Jan 10, 2029
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06209645
Responsible party
Sponsor
First posted
Jan 17, 2024
Start date
Apr 10, 2025
Primary completion
Jan 10, 2029 (estimated)
Completion
Jan 10, 2029 (estimated)
Last update
May 8, 2026

Study contacts

Charbel SALAMEH, MD
Contact
ext-charbel.salameh@chu-lyon.fr
00 33 4 72 35 78 29
GARCIA-LARREA Luis, MD., PhD
Contact
luis.garcia-larrea@univ-lyon1.fr
00 33 4 72 35 78 88
Charbel SALAMEH, MD
principal investigator · Central Integration of pain lab (NeuroPain); Lyon Neurocience research center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion